Variation in hypertension clinical practice guidelines: a global comparison

Abstract

Background Hypertension is the largest single contributor to the global burden of disease, affecting an estimated 1.39 billion people worldwide. Clinical practice guidelines (CPGs) can aid in the effective management of this common condition, however, inconsistencies exist between CPGs, and the extent of this is unknown. Understanding the differences in CPG recommendations across income settings may provide an important means of understanding some of the global variations in clinical outcomes related to hypertension. Aims This study aims to analyse the variation between hypertension CPGs globally. It aims to assess the variation in three areas: diagnostic threshold and staging, treatment and target blood pressure (BP) recommendations in hypertension. Methods A search was conducted on the MEDLINE repository to identify national and international hypertension CPGs from 2010 to May 2020. An additional country-specific grey-literature search was conducted for all countries and territories of the world as identified by the World Bank. Data describing the diagnosis, staging, treatment and target blood pressure were extracted from CPGs, and variations between CPGs for these domains were analysed. Results Forty-eight CPGs from across all World Bank income settings were selected for analysis. Ninety-six per cent of guidelines defined hypertension as a clinic-based BP of ≥140/90 mmHg, and 87% of guidelines recommended a target BP of < 140/90 mmHg. In the pharmacological treatment of hypertension, eight different first-step, 17 different second-step and six different third-step drug recommendations were observed. Low-income countries preferentially recommended diuretics (63%) in the first-step treatment, whilst high-income countries offered more choice between antihypertensive classes. Forty-four per cent of guidelines, of which 71% were from higher-income contexts recommended initiating treatment with dual-drug therapy at BP 160/100 mmHg or higher. Conclusion This study found that CPGs remained largely consistent in the definition, staging and target BP recommendations for hypertension. Extensive variation was observed in treatment recommendations, particularly for second-line therapy. Variation existed between income settings; low-income countries prescribed cheaper drugs, offered less clinician choice in medications and initiated dual therapy at later stages than higher-income countries. Future research exploring the underlying drivers of this variation may improve outcomes for hypertensive patients across clinical contexts.

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

“… 57 , 58 Some countries, such as Canada, Costa Rica, South Korea, and Taiwan, have achieved low hypertension prevalence or high control through both improved prevention and improving every stage of the treatment cascade. 30 , 59 Universal health insurance has been instrumental in achieving high effective coverage but should be complemented with primary care strengthening, evidence-based hypertension guidelines that are up to date and are adapted to the country contexts, 8 , 47 health workforce training, and a robust system of drug procurement and distribution. 30 Programmes should also be regularly assessed, both at the population level, as our work has done, and in health facilities to ensure accountability and stimulate improvement.…”

“…We restricted our analysis to men and women aged 30–79 years because hypertension prevalence is relatively low before age 30 years and because guidelines differ in thresholds and treatment targets in older ages. 8 …”

Práticas Interprofissionais De Preceptores Vinculados a Uma Universidade Pública Da Região Norte

“…A Hipertensão Arterial Sistêmica (HAS) é uma condição multifatorial, que depende de fatores genéticos/epigenéticos, ambientais e sociais, caracterizada por uma pressão arterial sistólica igual ou superior a 140 mmHg e pressão arterial diastólica igual ou superior a 90 mmHg (PHILIP et. al., 2021;BARROSO et.…”

Metabolic status and vascular endothelial structure in obese hypertensive patients treated with non-pharmacological therapies: A systematic review and meta-analysis

“…Hypertension is one of the most important risk factors for cardiovascular disease, which seriously endangers human health [1]. About 13.9 million people worldwide suffer from hypertension, resulting in about 10.4 million premature deaths each year [2]. The prevalence of obesity has increased with the continuous changes in lifestyle, dietary habits, and working environment.…”